{"id":45616,"date":"2015-08-27T22:15:00","date_gmt":"2015-08-27T22:15:00","guid":{"rendered":"https:\/\/wp2.inovestor.com\/2015\/08\/gilead-sciences-gild\/"},"modified":"2015-08-27T22:15:00","modified_gmt":"2015-08-27T22:15:00","slug":"gilead-sciences-gild","status":"publish","type":"post","link":"https:\/\/www.inovestor.com\/fr-ca\/2015\/08\/gilead-sciences-gild\/","title":{"rendered":"Gilead Sciences (GILD)"},"content":{"rendered":"

Dans l’analyse de contenu de cette semaine, nous nous penchons sur la compagnie Gilead Sciences (GILD), sans doute une des soci\u00e8t\u00e8s en biotechnologie les plus performantes d’un point de vue EVA. Gilead se sp\u00e8cialise dans le d\u00e8veloppement et la commercialisation de m\u00e8dicaments pour le traitement de maladies graves telles que le VIH et l’h\u00e8patite C. D’apr\u00e8s les donn\u00e8es de Street Insider (lien<\/a>), Gilead a battu les attentes des analystes 7 fois lors des 8 derniers trimestres, et s’est remis du \u00ac\u00b4 crash \u00ac\u00aa de lundi en seulement 2 jours. Download<\/span> <\/a><\/p>\n

La performance \u00e8conomique de Gilead est \u00e0 son point le plus \u00e8lev\u00e8 des 5 derni\u00e8res ann\u00e8es. L’\u00e8cart de performance (ROC – COC) g\u00e8n\u00e8r\u00e8 est astronomique \u00e0 41.5%.<\/p>\n

En plus d’\u00eatre en pleine croissance, les multiples auxquels se n\u00e8gocient pr\u00e8sentement les actions de GILD sont tr\u00e8s attrayants. La valeur intrins\u00e8que est pass\u00e8e de 133.95$ \u00e0 359.34$ en 2 trimestres, soit une hausse de 168%. Le ratio P\/VI qui en d\u00e8coule est de seulement 0.3, montrant un grand potentiel d’appr\u00e8ciation pour le titre. Cette hausse marqu\u00e8e de la valeur intrins\u00e8que a \u00e8t\u00e8 en grande partie caus\u00e8e par l’augmentation des ventes et profits issus de deux nouveaux m\u00e8dicaments pour le traitement de l’h\u00e8patite C; Harvoni et Sovaldi. La valeur de croissance future (FGV) de -26.3% d\u00e8montre \u00e8galement que la valeur des op\u00e8rations courantes (COV) de la compagnie est pr\u00e8sentement escompt\u00e8e, alors que celle-ci ne fait presque que monter depuis 5 ans.<\/p>\n

L’EVA de Gilead a toujours \u00e8t\u00e8 positif lors des 5 derni\u00e8res ann\u00e8es, et la croissance s’est grandement acc\u00e8l\u00e8r\u00e8e depuis d\u00e8cembre 2013. Au cours des 12 derniers mois, la compagnie a investi pr\u00e8s de 12G$ dans son capital, le faisant passer de 23.4G$ \u00e0 35.5G$. Durant cette m\u00eame p\u00e8riode, le Profit Net d’Op\u00e8rations Apr\u00e8s Imp\u221a\u00a5ts (NOPAT) a augment\u00e8 de 91.4%. On peut donc facilement dire que les investissements effectu\u00e8s ont rapidement port\u00e8 fruit.<\/p>\n

En terminant avec la performance comptable, Gilead a constamment g\u00e8n\u00e8r\u00e8 des niveaux \u00e8lev\u00e8s de fonds lib\u00e8r\u00e8s (Free Cash-Flow), et ceux-ci ont augment\u00e8 de 150% au cours des 12 derniers mois. Dernier fait important \u00e0 noter; Gilead a vers\u00e8 son premier dividende lors du 2e trimestre de 2015 et son rendement annuel attendu s’\u00e8l\u00e8ve actuellement \u00e0 1.59%.<\/p>\n","protected":false},"excerpt":{"rendered":"

Dans l’analyse de contenu de cette semaine, nous nous penchons sur la compagnie Gilead Sciences (GILD), sans doute une des soci\u00e8t\u00e8s en biotechnologie les plus performantes d’un point de vue EVA. Gilead se sp\u00e8cialise dans le d\u00e8veloppement et la commercialisation de m\u00e8dicaments pour le traitement de maladies graves telles que le VIH et l’h\u00e8patite C. […]<\/p>\n","protected":false},"author":14,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[6],"tags":[440],"class_list":["post-45616","post","type-post","status-publish","format-standard","hentry","category-intelligence","tag-gild"],"acf":[],"yoast_head":"\nGilead Sciences (GILD) - Inovestor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.inovestor.com\/fr-ca\/2015\/08\/gilead-sciences-gild\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Sciences (GILD)\" \/>\n<meta property=\"og:description\" content=\"Dans l’analyse de contenu de cette semaine, nous nous penchons sur la compagnie Gilead Sciences (GILD), sans doute une des soci\u00e8t\u00e8s en biotechnologie les plus performantes d’un point de vue EVA. Gilead se sp\u00e8cialise dans le d\u00e8veloppement et la commercialisation de m\u00e8dicaments pour le traitement de maladies graves telles que le VIH et l’h\u00e8patite C. […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.inovestor.com\/fr-ca\/2015\/08\/gilead-sciences-gild\/\" \/>\n<meta property=\"og:site_name\" content=\"Inovestor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Inovestor\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-08-27T22:15:00+00:00\" \/>\n<meta name=\"author\" content=\"Inovestor\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Inovestor_\" \/>\n<meta name=\"twitter:site\" content=\"@Inovestor_\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Inovestor\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.inovestor.com\/fr-ca\/2015\/08\/gilead-sciences-gild\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.inovestor.com\/fr-ca\/2015\/08\/gilead-sciences-gild\/\"},\"author\":{\"name\":\"Inovestor\",\"@id\":\"https:\/\/www.inovestor.com\/en-ca\/#\/schema\/person\/6616b197e129a7a95f3107103c871092\"},\"headline\":\"Gilead Sciences (GILD)\",\"datePublished\":\"2015-08-27T22:15:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.inovestor.com\/fr-ca\/2015\/08\/gilead-sciences-gild\/\"},\"wordCount\":404,\"publisher\":{\"@id\":\"https:\/\/www.inovestor.com\/en-ca\/#organization\"},\"keywords\":[\"GILD\"],\"articleSection\":[\"Intelligence\"],\"inLanguage\":\"fr-CA\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.inovestor.com\/fr-ca\/2015\/08\/gilead-sciences-gild\/\",\"url\":\"https:\/\/www.inovestor.com\/fr-ca\/2015\/08\/gilead-sciences-gild\/\",\"name\":\"Gilead Sciences (GILD) - Inovestor\",\"isPartOf\":{\"@id\":\"https:\/\/www.inovestor.com\/en-ca\/#website\"},\"datePublished\":\"2015-08-27T22:15:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.inovestor.com\/fr-ca\/2015\/08\/gilead-sciences-gild\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.inovestor.com\/fr-ca\/2015\/08\/gilead-sciences-gild\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.inovestor.com\/fr-ca\/2015\/08\/gilead-sciences-gild\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.inovestor.com\/fr-ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Sciences (GILD)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.inovestor.com\/en-ca\/#website\",\"url\":\"https:\/\/www.inovestor.com\/en-ca\/\",\"name\":\"Inovestor\",\"description\":\"Make investment decisions that matter most\",\"publisher\":{\"@id\":\"https:\/\/www.inovestor.com\/en-ca\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.inovestor.com\/en-ca\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.inovestor.com\/en-ca\/#organization\",\"name\":\"Inovestor\",\"url\":\"https:\/\/www.inovestor.com\/en-ca\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.inovestor.com\/en-ca\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.inovestor.com\/wp-content\/uploads\/2022\/04\/Inovestor-logo-high-res.png\",\"contentUrl\":\"https:\/\/www.inovestor.com\/wp-content\/uploads\/2022\/04\/Inovestor-logo-high-res.png\",\"width\":1581,\"height\":422,\"caption\":\"Inovestor\"},\"image\":{\"@id\":\"https:\/\/www.inovestor.com\/en-ca\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Inovestor\/\",\"https:\/\/x.com\/Inovestor_\",\"https:\/\/www.linkedin.com\/company\/inovestor\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.inovestor.com\/en-ca\/#\/schema\/person\/6616b197e129a7a95f3107103c871092\",\"name\":\"Inovestor\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/www.inovestor.com\/en-ca\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/87cd3105a1d74b889db7d26a60a8f3d3611a70d6e08baa4865bc6c8d091834b4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/87cd3105a1d74b889db7d26a60a8f3d3611a70d6e08baa4865bc6c8d091834b4?s=96&d=mm&r=g\",\"caption\":\"Inovestor\"},\"url\":\"https:\/\/www.inovestor.com\/fr-ca\/author\/inovestor\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead Sciences (GILD) - Inovestor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.inovestor.com\/fr-ca\/2015\/08\/gilead-sciences-gild\/","og_locale":"fr_CA","og_type":"article","og_title":"Gilead Sciences (GILD)","og_description":"Dans l’analyse de contenu de cette semaine, nous nous penchons sur la compagnie Gilead Sciences (GILD), sans doute une des soci\u00e8t\u00e8s en biotechnologie les plus performantes d’un point de vue EVA. Gilead se sp\u00e8cialise dans le d\u00e8veloppement et la commercialisation de m\u00e8dicaments pour le traitement de maladies graves telles que le VIH et l’h\u00e8patite C. […]","og_url":"https:\/\/www.inovestor.com\/fr-ca\/2015\/08\/gilead-sciences-gild\/","og_site_name":"Inovestor","article_publisher":"https:\/\/www.facebook.com\/Inovestor\/","article_published_time":"2015-08-27T22:15:00+00:00","author":"Inovestor","twitter_card":"summary_large_image","twitter_creator":"@Inovestor_","twitter_site":"@Inovestor_","twitter_misc":{"\u00c9crit par":"Inovestor","Estimation du temps de lecture":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.inovestor.com\/fr-ca\/2015\/08\/gilead-sciences-gild\/#article","isPartOf":{"@id":"https:\/\/www.inovestor.com\/fr-ca\/2015\/08\/gilead-sciences-gild\/"},"author":{"name":"Inovestor","@id":"https:\/\/www.inovestor.com\/en-ca\/#\/schema\/person\/6616b197e129a7a95f3107103c871092"},"headline":"Gilead Sciences (GILD)","datePublished":"2015-08-27T22:15:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.inovestor.com\/fr-ca\/2015\/08\/gilead-sciences-gild\/"},"wordCount":404,"publisher":{"@id":"https:\/\/www.inovestor.com\/en-ca\/#organization"},"keywords":["GILD"],"articleSection":["Intelligence"],"inLanguage":"fr-CA"},{"@type":"WebPage","@id":"https:\/\/www.inovestor.com\/fr-ca\/2015\/08\/gilead-sciences-gild\/","url":"https:\/\/www.inovestor.com\/fr-ca\/2015\/08\/gilead-sciences-gild\/","name":"Gilead Sciences (GILD) - Inovestor","isPartOf":{"@id":"https:\/\/www.inovestor.com\/en-ca\/#website"},"datePublished":"2015-08-27T22:15:00+00:00","breadcrumb":{"@id":"https:\/\/www.inovestor.com\/fr-ca\/2015\/08\/gilead-sciences-gild\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.inovestor.com\/fr-ca\/2015\/08\/gilead-sciences-gild\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.inovestor.com\/fr-ca\/2015\/08\/gilead-sciences-gild\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.inovestor.com\/fr-ca\/"},{"@type":"ListItem","position":2,"name":"Gilead Sciences (GILD)"}]},{"@type":"WebSite","@id":"https:\/\/www.inovestor.com\/en-ca\/#website","url":"https:\/\/www.inovestor.com\/en-ca\/","name":"Inovestor","description":"Make investment decisions that matter most","publisher":{"@id":"https:\/\/www.inovestor.com\/en-ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.inovestor.com\/en-ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.inovestor.com\/en-ca\/#organization","name":"Inovestor","url":"https:\/\/www.inovestor.com\/en-ca\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.inovestor.com\/en-ca\/#\/schema\/logo\/image\/","url":"https:\/\/www.inovestor.com\/wp-content\/uploads\/2022\/04\/Inovestor-logo-high-res.png","contentUrl":"https:\/\/www.inovestor.com\/wp-content\/uploads\/2022\/04\/Inovestor-logo-high-res.png","width":1581,"height":422,"caption":"Inovestor"},"image":{"@id":"https:\/\/www.inovestor.com\/en-ca\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Inovestor\/","https:\/\/x.com\/Inovestor_","https:\/\/www.linkedin.com\/company\/inovestor"]},{"@type":"Person","@id":"https:\/\/www.inovestor.com\/en-ca\/#\/schema\/person\/6616b197e129a7a95f3107103c871092","name":"Inovestor","image":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.inovestor.com\/en-ca\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/87cd3105a1d74b889db7d26a60a8f3d3611a70d6e08baa4865bc6c8d091834b4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/87cd3105a1d74b889db7d26a60a8f3d3611a70d6e08baa4865bc6c8d091834b4?s=96&d=mm&r=g","caption":"Inovestor"},"url":"https:\/\/www.inovestor.com\/fr-ca\/author\/inovestor\/"}]}},"_links":{"self":[{"href":"https:\/\/www.inovestor.com\/fr-ca\/wp-json\/wp\/v2\/posts\/45616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.inovestor.com\/fr-ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.inovestor.com\/fr-ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.inovestor.com\/fr-ca\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.inovestor.com\/fr-ca\/wp-json\/wp\/v2\/comments?post=45616"}],"version-history":[{"count":0,"href":"https:\/\/www.inovestor.com\/fr-ca\/wp-json\/wp\/v2\/posts\/45616\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.inovestor.com\/fr-ca\/wp-json\/wp\/v2\/media?parent=45616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.inovestor.com\/fr-ca\/wp-json\/wp\/v2\/categories?post=45616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.inovestor.com\/fr-ca\/wp-json\/wp\/v2\/tags?post=45616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}